What Is Diabetic Retinopathy?

Diabetic retinopathy is a microvascular complication of diabetes mellitus in which sustained high blood glucose damages the small blood vessels that supply the retina, causing them to weaken, leak, close off, or provoke the growth of abnormal replacement vessels. It is among the leading causes of preventable vision loss in working-age adults worldwide. The early stages usually produce no symptoms at all, which is why the condition is managed through scheduled screening rather than through patient-reported complaints.

The subject sits at the intersection of ophthalmology, endocrinology, and biomedical engineering. Because diagnosis rests almost entirely on interpreting retinal images, diabetic retinopathy has become one of the most heavily studied problems in medical image analysis and one of the first areas where automated diagnostic software reached regulatory approval.

Pathophysiology and Staging

Chronic hyperglycemia damages the pericytes and endothelial cells of retinal capillaries, producing microaneurysms, dot and blot hemorrhages, hard exudates from lipid leakage, and cotton wool spots where nerve fiber layer infarcts occur. Clinicians divide the course into non-proliferative and proliferative stages. Non-proliferative disease is graded mild, moderate, or severe according to the extent of these lesions across defined retinal fields. Proliferative disease begins when ischemia drives the release of vascular endothelial growth factor and new, fragile vessels grow on the retinal surface or optic disc, risking vitreous hemorrhage and tractional retinal detachment. Diabetic macular edema, fluid accumulation at the fovea, can occur at any stage and is the most common immediate cause of vision loss. The Early Treatment Diabetic Retinopathy Study scale established in the 1980s remains the reference grading system for both clinical trials and algorithm development.

Imaging and Screening

Screening centers on the dilated eye examination and on color fundus photography, and the National Eye Institute advises everyone with diabetes to have a dilated eye exam at least once a year. Optical coherence tomography provides micrometer-scale cross sections of the retina and is the standard tool for detecting and quantifying macular edema, while fluorescein angiography maps perfusion and leakage when the disease appears severe. Ultra-widefield imaging extends the visible field well beyond the seven standard photographic fields, and OCT angiography images capillary flow without an injected dye. Teleretinal screening programs, in which non-specialist staff capture images that are graded remotely, were developed to raise coverage in primary care and remote settings, and they generated the large labeled image archives that later supported machine learning.

Automated Detection and Machine Learning

Classical computer vision approaches detected individual lesion types through morphological filtering and hand-designed features. Since 2016, convolutional neural networks trained end to end on graded fundus photographs have matched the sensitivity and specificity of trained human graders on referable disease, a result discussed in a JAMA commentary on deep learning technology in diabetic retinopathy screening. A survey of deep learning based computer-aided diagnosis systems for diabetic retinopathy reviews the network architectures, public data sets such as EyePACS and Messidor, and the evaluation protocols used across this literature. Practical deployment raised further engineering questions: image quality assessment to reject ungradable photographs, calibration across camera models, generalization to populations absent from training data, and interpretability sufficient for clinical trust.

Applications

Work on diabetic retinopathy connects to a range of technical fields, including:

• Medical image analysis and pattern recognition
• Optical instrument design for fundus cameras and OCT systems
• Telemedicine and store-and-forward screening infrastructure
• Regulatory science for autonomous diagnostic software
• Health economics and population screening program design
• Drug delivery engineering for intravitreal anti-VEGF therapy
• Laser system design for panretinal photocoagulation